Alumis (ALMS) Shares Outstanding (Weighted Average) (2023 - 2025)
Alumis (ALMS) reported Shares Outstanding (Weighted Average) of $85.0 million for Q4 2025, up 197.51% year-over-year from $28.6 million in Q4 2024, and up 8.24% quarter-over-quarter from $78.6 million in Q3 2025.
Alumis (ALMS) Shares Outstanding (Weighted Average) (2023 - 2025) Analysis & Trends
Alumis (ALMS) has 3 years of Shares Outstanding (Weighted Average) data on file, last reported at $85.0 million in Q4 2025.
- Shares Outstanding (Weighted Average) for Q4 2025 came in at $85.0 million, up 197.51% year-over-year; the trailing twelve-month figure through Dec 2025 was $85.0 million (up 197.51% YoY), and the FY2025 annual result was $85.0 million, up 197.51% from the prior year.
- Shares Outstanding (Weighted Average) climbed to $85.0 million in Q4 2025 per ALMS's latest filing, from $78.6 million in the prior quarter.
- Over five years, Shares Outstanding (Weighted Average) peaked at $85.0 million in Q4 2025 and troughed at $2.1 million in Q3 2023.
- A 3-year average of $35.3 million and a median of $28.6 million in 2024 frame the typical range for Shares Outstanding (Weighted Average).
- The sharpest annual moves came in 2024 and 2025: Shares Outstanding (Weighted Average) decreased 7.21% in 2024, then surged 3029.96% in 2025.
- A 3-year view of Shares Outstanding (Weighted Average) shows it stood at $2.2 million in 2023, then jumped by 1229.19% to $28.6 million in 2024, then surged by 197.51% to $85.0 million in 2025.
- Business Quant data shows ALMS's Shares Outstanding (Weighted Average) at $85.0 million in Q4 2025, $78.6 million in Q3 2025, and $76.6 million in Q2 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Weighted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 185,491.37 Bn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 400.00 Bn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 100.00 Bn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | 417.01 Bn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 118.76 Bn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 68.88 Bn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 254.10 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 928.40 Mn |
| 10 | Alumis | 1.99 Bn | 1.90 Bn | - | 85.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 85.03 Mn |
| Sep 30, 2025 | 78.55 Mn |
| Jun 30, 2025 | 76.56 Mn |
| Mar 31, 2025 | 54.41 Mn |
| Dec 31, 2024 | 28.58 Mn |
| Sep 30, 2024 | 53.97 Mn |
| Jun 30, 2024 | 2.45 Mn |
| Mar 31, 2024 | 2.37 Mn |
| Dec 31, 2023 | 2.15 Mn |
| Sep 30, 2023 | 2.10 Mn |
| Jun 30, 2023 | 2.64 Mn |